155 completed. 155 Phase 3, 6 Phase 2.
By phase and status
Follow Dermatitis, Atopic: new trials by email Literature Review of Dermatitis, Atopic trials Research Report on Dermatitis, Atopic
Trials (filtered) newest first · largest first
All 155 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis
Roflumilast Cream 0.15%, Vehicle cream - Atopic Dermatitis (AD) | Phase 3 | Completed | 354 | 2024-11-21 | 2025-09-02 |
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
611, Placebo, Topical corticosteroid - Dermatitis, Atopic, Eczema, Atopic | Phase 3 | Completed | 417 | 2024-09-23 | 2026-09-17 |
A Study to Evaluate the Efficacy and Safety of SIM0718 in Adult and Adolescent Patients With Moderate to Severe Atopic Dermatitis
SIM0718 Injection - Atopic Dermatitis | Phase 3 | Completed | 259 | 2024-07-04 | 2026-03-31 |
Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis
Lebrikizumab Pen - Atopic Dermatitis | Phase 3 | Completed | 55 | 2024-06-04 | 2025-07-29 |
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
Ruxolitinib Cream, Vehicle Cream - Atopic Dermatitis | Phase 3 | Completed | 241 | 2024-04-26 | 2026-10-15 |
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
Placebo, Lebrikizumab, Topical Corticosteroid - Atopic Dermatitis | Phase 3 | Completed | 301 | 2024-04-24 | 2026-10-16 |
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis
Rocatinlimab Prefilled Syringe, Rocatinlimab AI - Atopic Dermatitis | Phase 3 | Completed | 151 | 2024-04-02 | 2026-03-25 |
Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis
CM310, placebo - Atopic Dermatitis | Phase 3 | Completed | 180 | 2024-03-21 | 2025-10-02 |
A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.
LNK01001, Placebo - Atopic Dermatitis | Phase 3 | Completed | 356 | 2024-02-06 | 2026-04-13 |
Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis
611, Matching placebo - Dermatitis, Atopic | Phase 3 | Completed | 519 | 2024-01-22 | 2026-01-15 |
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
Amlitelimab, Placebo, Topical corticosteroids - Dermatitis Atopic | Phase 3 | Completed | 643 | 2024-01-18 | 2026-08-13 |
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
Amlitelimab, Placebo - Dermatitis Atopic | Phase 3 | Completed | 589 | 2023-12-21 | 2026-08-13 |
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
Lebrikizumab - Atopic Dermatitis, Eczema | Phase 3 | Completed | 260 | 2023-11-20 | 2026-07-17 |
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Amlitelimab, Placebo - Dermatitis Atopic | Phase 3 | Completed | 601 | 2023-11-08 | 2026-07-22 |
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
Tralokinumab, Placebo - Atopic Dermatitis, Atopic Hand Eczema | Phase 3 | Completed | 235 | 2023-08-28 | 2026-10-22 |
A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis
MH004 Ointment, Vehicle Ointment - Atopic Dermatitis (AD) | Phase 3 | Completed | 375 | 2023-06-10 | 2025-09-22 |
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
Rocatinlimab, Placebo - Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis | Phase 3 | Completed | 221 | 2023-06-07 | 2026-07-23 |
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
Lebrikizumab - Atopic Dermatitis | Phase 3 | Completed | 174 | 2023-05-23 | 2026-05-14 |
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Rocatinlimab, Placebo - Atopic Dermatitis | Phase 3 | Completed | 532 | 2023-04-20 | 2026-08-28 |
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
Rocatinlimab, Placebo - Atopic Dermatitis | Phase 3 | Completed | 746 | 2023-02-21 | 2026-08-06 |
Showing 20 of 155. Sign in to see all of them.
Narrower conditions
Eczema (50) · Dermatitis (17) · Skin Diseases (13) · Pruritus (6) · Genetic Diseases, Inborn (4) · Hypersensitivity (4) · Hypersensitivity, Immediate (4) · Immune System Diseases (4) · Skin Diseases, Eczematous (4) · Skin Diseases, Genetic (4) · Asthma (2) · Rhinitis, Allergic (1)
Broader conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (155) · Skin and Connective Tissue Diseases (155) · Genetic Diseases, Inborn (151) · Hypersensitivity (151) · Hypersensitivity, Immediate (151) · Immune System Diseases (151) · Skin Diseases, Eczematous (151) · Skin Diseases, Genetic (151) · Skin Diseases (142) · Dermatitis (138) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Skin Manifestations (6) · Bronchial Diseases (2) · Lung Diseases (2)
Interventions
dupilumab (16) · lebrikizumab (13) · Adrenal Cortex Hormones (12) · tralokinumab (9) · abrocitinib (8) · pimecrolimus (8) · baricitinib (7) · difamilast (7) · Tacrolimus (6) · upadacitinib (6) · Cyclosporine (3) · Desonide (2) · desloratadine (2) · entacapone (2) · nemolizumab (2)
Sponsors
Eli Lilly and Company (18) · Pfizer (12) · Regeneron Pharmaceuticals (10) · LEO Pharma (9) · Amgen (7) · AbbVie (6) · Astellas Pharma Inc (6) · Sanofi (6) · Incyte Corporation (5) · Organon and Co (5) · Otsuka Pharmaceutical Co., Ltd. (4) · Almirall, S.A. (3) · Novartis (3) · Acrotech Biopharma Inc. (2) · Bausch Health Americas, Inc. (2)
Countries
United States (75) · Germany (53) · Canada (49) · Poland (49) · Spain (38) · Japan (37) · United Kingdom (35) · Italy (33) · France (32) · Australia (30) · China (30) · South Korea (29) · Czechia (26) · Hungary (25) · Netherlands (22)
Top investigators
Diana Villalobos (3) · Osamu Sato (3) · Brett Angel, MD (2) · Dr. Nikhil Sawant (2) · Jason Wu (2)
Results publications
PMID 39588375, PMID 42162528, PMID 33826132, PMID 40993471, PMID 34406619, PMID 36255569, PMID 36723913, PMID 38896380, PMID 40028832, PMID 31066001, PMID 33165005, PMID 33453450, PMID 34142350, PMID 35636689, PMID 36808602, PMID 39104653, PMID 40555305, PMID 41118053, PMID 31407311, PMID 31424712, PMID 34037993, PMID 34275122, PMID 34688290, PMID 34726270, PMID 34743361, PMID 34897582, PMID 35342978, PMID 36152216, PMID 36749121, PMID 38777187, PMID 39110139, PMID 40085349, PMID 40383273, PMID 40457140, PMID 40600584, PMID 41206702, PMID 42365219, PMID 27417017, PMID 27690741, PMID 28503712, PMID 30345457, PMID 30791102, PMID 32318744, PMID 32574023, PMID 33000465, PMID 33222559, PMID 33481203, PMID 33658996, PMID 33728583, PMID 33899152
NIH funding
2018 (10), 2017 (8), 2019 (7), 2023 (5), 2016 (4), 2015 (2), 2014 (1)